Want to see IN:DCAL full AI Analyst Report?
DCAL Stock Chart & Stats
₹255.15
-₹14.00(-4.80%)
At close: 4:00 PM EST
₹255.15
-₹14.00(-4.80%)
Day’s Range― - ―
52-Week Range₹129.00 - ₹305.50
Previous CloseN/A
Volume578.20K
Average Volume (3M)12.64K
Market Cap
₹23.35B
Enterprise Value₹40.88B
Total Cash (Recent Filing)₹10.07B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)34.6
Beta1.41
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.11%
Share Statistics
EPS (TTM)4.35
Shares Outstanding156,783,100
10 Day Avg. Volume9,037
30 Day Avg. Volume12,645
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.69
P/FCF Ratio26.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Operating Cash FlowConsistently positive operating cash flow indicates that the core business is converting activity into cash despite fluctuations in reported earnings. This supports ongoing operations and provides internal funding capacity, although the quality of conversion still depends on improving free cash flow consistency.
Broad CDMO CapabilitiesDCAL’s coverage from process development through commercial API and intermediate manufacturing gives it multiple opportunities to participate in a customer molecule’s lifecycle. This integrated capability can support customer retention and deepen relationships as projects progress toward larger-scale supply.
Manageable Leverage And Equity BaseA substantial equity base and moderate reported leverage provide a financial foundation for operating through business volatility. This balance-sheet position should offer more flexibility than a highly leveraged structure, although the benefit is tempered by rising debt and inconsistent returns on equity.
Bears Say
Volatile ProfitabilityLarge swings between losses and profits make earnings power difficult to assess and reduce confidence that recent improvement will persist. Inconsistent margins can constrain planning, weaken reinvestment visibility, and leave results more exposed to execution and operating conditions.
Rising Debt BurdenIncreasing debt raises the financial commitments attached to the business and can reduce flexibility if profitability weakens. Even with manageable leverage today, further borrowing alongside uneven returns could increase pressure on cash allocation and make future growth more dependent on execution.
Uneven Free Cash FlowThe recovery in free cash flow is encouraging, but prior negative periods and sharply changing growth rates show that cash available after investment has not been dependable. This may limit confidence in self-funded expansion and increase reliance on operating improvement or external financing.
Dishman Carbogen Amcis Ltd. News
DCAL FAQ
What was Dishman Carbogen Amcis Ltd.’s price range in the past 12 months?
Dishman Carbogen Amcis Ltd. lowest stock price was ₹129.00 and its highest was ₹305.50 in the past 12 months.
What is Dishman Carbogen Amcis Ltd.’s market cap?
Dishman Carbogen Amcis Ltd.’s market cap is ₹23.35B.
When is Dishman Carbogen Amcis Ltd.’s upcoming earnings report date?
Dishman Carbogen Amcis Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 22 days.
How were Dishman Carbogen Amcis Ltd.’s earnings last quarter?
Dishman Carbogen Amcis Ltd. released its earnings results on Aug 14, 2026. The company reported -₹0.369 earnings per share for the quarter.
Is Dishman Carbogen Amcis Ltd. overvalued?
According to Wall Street analysts Dishman Carbogen Amcis Ltd.’s price is currently Overvalued.
Does Dishman Carbogen Amcis Ltd. pay dividends?
Dishman Carbogen Amcis Ltd. pays a Notavailable dividend of ₹0.2 which represents an annual dividend yield of 0.11%. See more information on Dishman Carbogen Amcis Ltd. dividends here
What is Dishman Carbogen Amcis Ltd.’s EPS estimate?
Dishman Carbogen Amcis Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dishman Carbogen Amcis Ltd. have?
Dishman Carbogen Amcis Ltd. has 156,783,100 shares outstanding.
What happened to Dishman Carbogen Amcis Ltd.’s price movement after its last earnings report?
Dishman Carbogen Amcis Ltd. reported an EPS of -₹0.369 in its last earnings report. Following the earnings report the stock price went down -4.081%.
Which hedge fund is a major shareholder of Dishman Carbogen Amcis Ltd.?
Currently, no hedge funds are holding shares in IN:DCAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dishman Carbogen Amcis Ltd.
Established in 1983 and headquartered in Ahmedabad, India, Dishman Carbogen Amcis Limited provides specialized contract research and manufacturing solutions to the worldwide pharmaceutical sector. The company operates through two main business segments: Contract Research and Manufacturing Services (CR&MS), and Marketable Molecules. Beyond its core services, it manufactures and distributes an extensive portfolio of products, including bulk drugs, chemical intermediates, various phase transfer catalysts, quaternary ammonium compounds, phosphoranes, wittig reagents, vitamin D derivatives, and fine chemicals. Additionally, its offerings encompass personal care products like hand and body washes, sanitizers, and antiseptics, as well as a range of pharmaceutical and cosmetic formulations, including generic and highly potent active pharmaceutical ingredients. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
Technical Analysis
Biocon Limited
―
Blue Jet Healthcare Limited
―
Concord Biotech Ltd.
―
Syngene International Ltd.
―
OneSource Specialty Pharma Limited
―